To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01123707 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
173
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early due to Sponsor decision; no safety issues.

Conditions

Interventions

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.